Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
PGN-EDO51 in Muscular Dystrophy, Duchenne: NCT06079736 Clinical Landscape Report 2026
18 September 2026
NCT06079736 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JWK-007 in Muscular Dystrophy, Duchenne: NCT06114056 Clinical Landscape Report 2026
18 September 2026
NCT06114056 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SGT-003 in Tabes Dorsalis: NCT06138639 Clinical Landscape Report 2026
18 September 2026
NCT06138639 clinical landscape for Tabes Dorsalis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Imlifidase in Muscular Dystrophy, Duchenne: NCT06241950 Clinical Landscape Report 2026
18 September 2026
NCT06241950 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sevasemten in Muscular Dystrophy, Duchenne: NCT06100887 Clinical Landscape Report 2026
18 September 2026
NCT06100887 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Delandistrogene moxeparvovec in Muscular Dystrophy, Duchenne: NCT06128564 Clinical Landscape Report 2026
18 September 2026
NCT06128564 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tadalafil in Muscular Dystrophy, Duchenne: NCT06290713 Clinical Landscape Report 2026
18 September 2026
NCT06290713 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SRD-001 in DMD-Associated Dilated Cardiomyopathy: NCT06224660 Clinical Landscape Report 2026
18 September 2026
NCT06224660 clinical landscape for DMD-Associated Dilated Cardiomyopathy: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Delpacibart zotadirsen in Exon 44 Skipping Mutation Duchenne Muscular Dystrophy: NCT06244082 Clinical Landscape Report 2026
18 September 2026
NCT06244082 clinical landscape for Exon 44 Skipping Mutation Duchenne Muscular Dystrophy: endpoints, sponsor, phase, geography, readouts, asset context and d…
9 min read
BMN-351 in Muscular Dystrophy, Duchenne: NCT06280209 Clinical Landscape Report 2026
18 September 2026
NCT06280209 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bemiltenase alfa in Hemophilia B: NCT06289166 Clinical Landscape Report 2026
18 September 2026
NCT06289166 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant coagulation factor VIII(Chia Tai-Tianqing) in Hemophilia A: NCT06297655 Clinical Landscape Report 2026
18 September 2026
NCT06297655 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.